<div id="readability-page-1"><p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $58.00, but opened at $53.37. Hims &amp; Hers Health shares last traded at $54.38, with a volume of 15,902,838 shares.</p><div><p><span></span><span>Get <strong>Hims &amp; Hers Health</strong> alerts:</span></p></div><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Will Hims &amp; Hers Stock Be Okay After UnitedHealth's Sell-Off?</li></ul><p>HIMS has been the subject of several research analyst reports. UBS Group  reiterated a &#34;mixed&#34; rating on shares of Hims &amp; Hers Health in a research note on Tuesday, May 6th. Canaccord Genuity Group increased their target price on shares of Hims &amp; Hers Health from $38.00 to $68.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, February 19th. Needham &amp; Company LLC  reissued a &#34;buy&#34; rating and set a $61.00 target price on shares of Hims &amp; Hers Health in a research report on Tuesday, May 6th. Citigroup  reaffirmed a &#34;sell&#34; rating and issued a $30.00 price target (up previously from $25.00) on shares of Hims &amp; Hers Health in a report on Tuesday, May 6th. Finally, Piper Sandler  reiterated a &#34;neutral&#34; rating and issued a $39.00 price objective (up previously from $35.00) on shares of Hims &amp; Hers Health in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eight have issued  a hold rating and four have assigned  a buy rating to the company's stock. Based on data from MarketBeat, Hims &amp; Hers Health  has a consensus rating of &#34;Hold&#34; and a consensus target price of $37.67.</p><p><b>Read Our Latest Analysis on Hims &amp; Hers Health</b></p><h2>Hims &amp; Hers Health Stock Down 3.0%</h2><ul><li>Hims &amp; Hers Stock Chart Points to Strong Bullish Continuation</li></ul><p>The stock has a market capitalization of $12.59 billion, a P/E ratio of 127.74 and a beta of 1.84. The business has a 50-day simple moving average of $37.10 and a two-hundred day simple moving average of $34.54. </p><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims &amp; Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company's revenue was up 110.7% on a year-over-year basis. During the same quarter last year, the business posted $0.05 earnings per share.  On average, sell-side analysts forecast that  Hims &amp; Hers Health, Inc. will post 0.29 earnings per share for the current year. </p><h2>Insiders Place Their Bets</h2><ul><li>Hims &amp; Hers Stock Rises on Fundamentals and Squeeze Potential</li></ul><p>In related news, insider Patrick Harrison Carroll sold 23,287 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total value of $798,976.97. Following the transaction, the insider now owns 209,661 shares in the company, valued at $7,193,468.91. This trade represents a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $60.22, for a total transaction of $697,407.82. Following the sale, the chief financial officer now directly owns 113,816 shares of the company's stock, valued at approximately $6,853,999.52. This trade represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 618,936 shares of company stock valued at $25,182,692. 13.71% of the stock is currently owned by corporate insiders. </p><h2>Hedge Funds Weigh In On Hims &amp; Hers Health</h2><p>Institutional investors and hedge funds have recently made changes to their positions in the company. Farallon Capital Management LLC raised its position in shares of  Hims &amp; Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares during the period.  Arrowstreet Capital Limited Partnership increased its stake in  Hims &amp; Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter.  Vanguard Group Inc. raised its holdings in  Hims &amp; Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after buying an additional 2,020,722 shares during the period.  Nuveen LLC bought a new position in  Hims &amp; Hers Health in the first quarter valued at approximately $58,403,000.  Finally, Yong Rong HK Asset Management Ltd bought a new stake in  Hims &amp; Hers Health in the 4th quarter valued at $41,104,000. Institutional investors and hedge funds own  63.52% of the company's stock. </p><h2>About Hims &amp; Hers Health</h2> (Get Free Report)<p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA. </p><h2>See Also</h2><ul><li>Five stocks we like better than Hims &amp; Hers Health</li><li>Insider Selling Explained: Can it Inform Your Investing Choices?</li><li>3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market</li><li>3 Healthcare Dividend Stocks to Buy</li><li>These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1</li><li>How to Invest in Biotech Stocks</li><li>Buy the Dip? 3 Oil Stocks Poised for a Big Comeback</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HIMS

<p>Hims & Hers Health (NYSE:HIMS) shares gapped down from $58.00 to $53.37 before trading, closing at $54.38 with a volume of 15,902,838 shares. Analysts have mixed ratings, with target prices ranging from $30.00 to $68.00. The company reported $0.20 EPS, exceeding estimates, and revenue of $586.01 million, up 110.7% year-over-year. Insiders sold significant shares recently, and institutional investors have increased their stakes. The stock has a market cap of $12.59 billion and a consensus rating of "Hold" with a target price of $37.67.</p>

Hims & Hers Health (NYSE:HIMS) Shares Gap Down - Here's Why